WO2022052794A1 - 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 - Google Patents

一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 Download PDF

Info

Publication number
WO2022052794A1
WO2022052794A1 PCT/CN2021/113937 CN2021113937W WO2022052794A1 WO 2022052794 A1 WO2022052794 A1 WO 2022052794A1 CN 2021113937 W CN2021113937 W CN 2021113937W WO 2022052794 A1 WO2022052794 A1 WO 2022052794A1
Authority
WO
WIPO (PCT)
Prior art keywords
powder
infant formula
milk
milk powder
total
Prior art date
Application number
PCT/CN2021/113937
Other languages
English (en)
French (fr)
Inventor
陈历俊
陈璟瑶
赵军英
刘妍
刘茜
刘斌
乔为仓
Original Assignee
北京三元食品股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京三元食品股份有限公司 filed Critical 北京三元食品股份有限公司
Priority to AU2021340764A priority Critical patent/AU2021340764B2/en
Publication of WO2022052794A1 publication Critical patent/WO2022052794A1/zh
Priority to US18/172,992 priority patent/US20230263179A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C3/00—Preservation of milk or milk preparations
    • A23C3/02—Preservation of milk or milk preparations by heating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
    • A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the application relates to the field of food engineering, in particular to an infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides and a preparation method thereof.
  • the structure and function of the gastrointestinal tract of the infant rapidly adapts to the transition from parenteral nutrition (placenta) to enteral nutrition (colostrum/milk powder) after delivery, in a process that is accompanied by dynamic microbial colonization.
  • parenteral nutrition placenta
  • enteral nutrition colon/milk powder
  • the initial establishment of the gut microbiota during infancy which is involved in the multiple interactions of gut development, metabolic homeostasis, and immune defense, lays a key foundation for long-term health later in life.
  • neonatal gut development and microbial colonization represent a window of opportunity for lifelong health.
  • the gut microbiome after birth is highly plastic and susceptible to nutrient intake and the surrounding environment during infancy, a superior integrity and functional gut is required for healthy host growth.
  • the colonizing microbiota is involved in nutrient metabolism, and its metabolites also contribute to the integrity of the intestinal barrier.
  • early bacterial optimal colonization affects barrier function and plays a critical role in gut development and neona
  • Human milk is the most ideal natural food for infants, and it is known that there are more than 2,000 components in human milk.
  • Human milk proteins can also be divided into three groups: mucins, casein and whey.
  • Mucin also known as milk fat globule membrane protein (MFGM)
  • MFGM milk fat globule membrane protein
  • the lipids of the milk fat globule membrane are mainly composed of neutral and polar lipids, and a small amount of glycolipids.
  • Phospholipids are polar lipids and the main component of lipids, which can promote the absorption and transport of fat digestion products in the digestive tract. At the same time, phospholipids are also involved in immune regulation and nerve signal transduction.
  • the main phospholipids present in human milk fat globules include sphingomyelin (SM), lecithin (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidylinositol (PI).
  • SM sphingomyelin
  • PC lecithin
  • PS phosphatidylserine
  • PE phosphatidylethanolamine
  • PI phosphatidylinositol
  • Neutral lipids of milk fat globule membranes such as triglycerides (TAG), diglycerides (DAG), cholesterol and their lipids.
  • GOS and FOS are prebiotics that are selectively utilized by host microorganisms, conferring their role in health.
  • Studies of GOS and FOS showed a preference for colonization by beneficial bacteria, such as lactobacillus, which had similar effects on the metabolic activity of the microbiota as breast milk oligosaccharides.
  • beneficial bacteria such as lactobacillus
  • GOS and FOS also have good applications in intestinal development and immune response.
  • GOS and FOS are prebiotics that produce short chain fatty acids (SCFAs) by fermentation of intestinal flora, which have important effects on intestinal development and growth. beneficial effect.
  • SCFAs short chain fatty acids
  • milk-derived milk fat globule membrane exhibits trophic bioactivity in metabolic regulation and intestinal homeostasis.
  • MFGM milk-derived milk fat globule membrane
  • intestinal development and microbial colonization in infancy are key steps in the growth phase.
  • Most of the previous studies on MFGM research and application focused on component separation, identification, and verification of its functional properties through metabolomics.
  • the effects of microbiota colonization, gut micro-ecosystem development, and barrier integrity are unclear; a mixed intervention of GOS and MFGM interventions has been reported to improve neurodevelopment in piglets.
  • the combined effects of GOS, MFGM, and FOS on gut microbial composition and gut development remain unclear.
  • the purpose of this application is to provide an infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides.
  • the milk powder is prepared with raw milk as raw material, added with MFGM-rich whey protein powder, ⁇ -lactalbumin powder, galactooligosaccharides and polyfructose, and is formulated to enhance the biologically active substance MFGM with special functional ingredients.
  • lactoferrin lactoferrin
  • alpha-lactalbumin alpha-La
  • total galactooligosaccharides GOS
  • total polyfructose FOS
  • sialic acid sialic acid
  • total phospholipids sphingomyelin (SM), egg Phosphatidylserine (PC), Phosphatidylserine (PS), Phosphatidylethanolamine (PE) and Phosphatidylinositol (PI), Ganglioside (Gang), Triglyceride (TAG), Diglyceride (DAG)
  • SM sphingomyelin
  • PC egg Phosphatidylserine
  • PS Phosphatidylserine
  • PE Phosphatidylethanolamine
  • PI Phosphatidylinositol
  • Ganglioside Gang
  • TAG Triglyceride
  • DAG Digly
  • the application provides an infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides, which uses raw cow milk as raw material, and is filled with MFGM-rich whey protein powder, ⁇ -lactalbumin powder, oligosaccharide It is prepared from lactose and polyfructose; wherein the content of functional active ingredients in every 100 grams of the infant formula milk powder is total MFGM-protein 0.146-0.438g, total ⁇ -lactalbumin 0.22-0.35g, total lactoferrin 0.2 -0.6g, immunoglobulin IgG0.1-0.3g, lactagglutinin 0.025-0.075g, MUC1/Mucin1 0.035-0.105g, total galactooligosaccharide 0.015-0.4g, total polyfructose 0.001-0.003g, saliva Acid 0.05-0.15g, total phospholipid 0.175-0.525g, sphingomyelin 0.04-0.12g
  • Table 1 Contents of functional active ingredients in infant formula with promoting gut health
  • infant formula milk powder wherein according to 1 ton of infant formula milk powder, the addition amount of MFGM-rich whey protein powder is 25kg-75kg, the addition amount of ⁇ -lactalbumin powder is 8kg-75kg, and the addition amount of galactooligosaccharide is 44kg- 133kg and polyfructose addition amount of 1.8kg-5.5kg; bovine colostrum is made into 15-16kg bovine colostrum powder according to 100L fresh milk.
  • the formula milk powder for infants and young children added and prepared according to the above ratio has a higher total active ingredient of alpha-lactalbumin.
  • the amount of fructose added is 4kg-5kg.
  • Bovine milk ⁇ -lactalbumin is only 76% identical in amino acid sequence to human milk ⁇ -lactalbumin.
  • ⁇ -lactalbumin has very high nutritional value for infants, and its amino acid composition is very similar to infant amino acid requirements and amino acid patterns.
  • Alpha-lactalbumin has been shown to be a part of lactose synthase and is involved in the synthesis of lactose in the mammary gland. Lactose synthase consists of two proteins, ⁇ -lactalbumin and galactosyltransferase, which together catalyze the binding of glucose to UDP-galactose.
  • ⁇ -lactalbumin When ⁇ -lactalbumin is digested in the intestines of infants, the peptides produced have antibacterial and immune-enhancing effects; the recently discovered ⁇ -lactalbumin multimers also have anti-infection and apoptosis-promoting effects. It is important to protect the intestinal health of infants.
  • the formula of the present application is specially filled with alpha-lactalbumin to synergistically improve the intestinal health of infants.
  • infant formula milk powder of the present application can also be added to the above-mentioned infant formula milk powder of the present application.
  • the resulting infant formula has the effect of promoting the intestinal health of infants.
  • the present application provides a method for preparing infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides, comprising the following steps: using raw cow milk as raw milk, and performing pre-sterilization (85°C-88°C, 30s), add MFGM whey protein powder, alpha-lactalbumin powder, galactooligosaccharide, polyfructose and other ingredients to the pre-sterilized raw milk, pre-sterilize (85°C-88°C, 30s), homogenize 15mPa, sterilization (93°C-95°C, 15s), concentration, spray drying (inlet air temperature 150°C-160°C, outlet air temperature 85°C-90°C).
  • Another specific embodiment of the present application relates to a high-throughput sequencing technology for sequencing and analyzing the 16S rDNA gene in piglet feces, and the influence of the formula milk powder of the present application on growth and intestinal flora composition is investigated.
  • the formula milk powder developed in the present application can promote the intestinal health of infants.
  • MFGM-rich whey protein powder, alpha-lactalbumin powder, galactooligosaccharides and polyfructose By adding MFGM-rich whey protein powder, alpha-lactalbumin powder, galactooligosaccharides and polyfructose, the total amount of the formula with special functional effects can be improved.
  • MFGM-protein, galacto-oligosaccharide, polyfructose, lactoferrin, ⁇ -lactalbumin, IgG, lactagglutinin, MUC1/Mucin1, phospholipids, gangliosides, sphingomyelin and sialic acid various functional active ingredients content to make it as close as possible to breast milk.
  • Fig. 1 is the composition of the fecal flora of the newborn piglet on the eighth day of Example 1 of the present application:
  • panel A is diversity (Sobs index); panel B is Shannon index (Shannon index); panel C is ⁇ -diversity of PCoA based on unweighted Unifrac distance; panel D is differential microbial composition based on Wilconxon rank sum test; E is linear sex analysis effect size (LefSe) analysis at the genus level, linear discriminant analysis (LDA) score >4; *P ⁇ 0.05; **P ⁇ 0.01.
  • Fig. 2 is the fecal flora composition on the 21st day of the newborn piglet of the embodiment of the present application 1:
  • panel A is diversity (Sobs index); panel B is Shannon index (Shannon index); panel C is ⁇ -diversity of PCoA based on unweighted Unifrac distance; panel D is differential microbial composition based on Wilconxon rank sum test; E is linear sex analysis effect size (LefSe) analysis at the genus level, linear discriminant analysis (LDA) score >4; *P ⁇ 0.05; **P ⁇ 0.01.
  • Fig. 3 is the functional status of the intestinal flora of newborn piglets of Example 1 of the present application:
  • Figure A is the differential abundance of Kyoto Encyclopedia of Genes and Genomes (KEGG) on the eighth day;
  • Figure B is the differential abundance of Kyoto Encyclopedia of Genes and Genomes (KEGG) on the twenty-first day.
  • Fig. 4 is the influence of the expression of genes related to intestinal barrier and intestinal permeability of newborn piglets in Example 1 of the present application 1 day 21:
  • A-C ileal mucosa
  • D-F colonic mucosa
  • G plasma DAO levels
  • Fig. 5 is the effect of piglet feces SCFAs concentration and intestinal GPRs gene of Example 1 of the present application:
  • Panel A shows the difference in the concentration of short-chain fatty acids in piglet feces
  • panel B shows the expression of receptor genes.
  • FIG. 6 is a production flow chart of the present application of Example 1 of the present application.
  • the active ingredients of the formula milk powder of the present application are more comprehensively close to breast milk, especially total ⁇ -lactalbumin, lecithin, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, diglyceride, triglyceride are all Ingredient not present in CN106359604A.
  • the amount of total lactoferrin was nearly 10 times higher than that of the control group, and the gap was reduced with breast milk.
  • the active ingredients in Table 2 were prepared according to the following method, and the wet processing process was adopted, as shown in FIG. 6 .
  • the main process parameters in the above method are: the pre-sterilization (85°C-88°C, 30s); homogenization 15mPa; sterilization (93°C-95°C, 15s); spray drying (inlet air temperature 150°C-160°C, out Wind temperature 85°C-90°C).
  • Selected 16 piglets (1.53 ⁇ 0.04 kg) from different litters (one piglet per litter) were randomly assigned to the control group fed normal saline (referred to as the CON group) and the experimental group fed galactooligosaccharides, MFGM whey protein powder, ⁇ -lactalbumin powder, galacto-oligosaccharide, polyfructose (abbreviated as GMF group, Example 1 of this application). From the first day to the seventh day of the new birth, the piglets in the GMF group were given 5 mL GMF solution (1 g/kg body weight) every day, and the piglets in the CON group were fed the same amount of normal saline. Piglets consume sow milk and water normally throughout the lactation period.
  • DAO diamine oxidase
  • immunoglobulins including IgA, IgG and IgM
  • Intestinal samples were removed from 10% phosphate buffered formalin, dehydrated through a graded ethanol series (70%-100%), then cleared with xylene, and embedded in paraffin.
  • Serial sections (5 ⁇ m thick), using an imaging microscope, were measured for at least 15 intact and well-oriented villi and their associated crypt magnification for each fragment.
  • Villus height was measured from the villus tip to the villus-crypt junction, and crypt depth was defined as the invagination depth between adjacent villi.
  • V3-V4 region of the 16S rRNA gene was amplified with primers and purified with the Axy PrepDNA Gel Extraction Kit. Then, the purified PCR products were pooled in equimolar amounts and sequenced on the platform.
  • the GMF group significantly increased the body weight of the piglets on day 8 and day 14 (P ⁇ 0.05) compared with the piglets in the CON group.
  • the average daily gain on days 1-8, 1-21 and the whole cycle (day 1-21) in the GMF group were significantly increased (P ⁇ 0.05).
  • the IgG concentration in piglet plasma on day 21 was significantly increased after GMF feeding (p ⁇ 0.05), while other parameters such as Glu, IgA, IGM, TG, HDL-c and LDL-c were not different.
  • Buttermophilin (BTN), mucin (MUC), xanthine oxidoreductase (XOR), lactadherin (MFG-E8) and fatty acid binding protein (FABP) have different biochemical properties.
  • BTN Buttermophilin
  • MUC mucin
  • XOR xanthine oxidoreductase
  • FMG-E8 lactadherin
  • FABP fatty acid binding protein
  • the 16S rRNA high-throughput sequencing technology was used to evaluate the microbial diversity, composition and differences.
  • the fecal flora of piglets on the 8th day of life is shown in Figure 1.
  • the ⁇ -diversity index analysis showed that the diversity (Sobs) index of the GMF group decreased significantly (P ⁇ 0.05) (Figure 1A), while the Shannon index did not change (Figure 1B).
  • ⁇ -diversity, PCoA analysis showed significant difference between CON group and GMF group (Fig. 1C); From the perspective of flora composition, the differential flora of piglets showed that GMF could significantly enrich Lactobacillus and reduce unclassified bacteria (Fig. 1C). P ⁇ 0.05) (Fig. 1D).
  • Linear discriminant analysis effect size (LEfSe) analysis also confirmed a significant increase in Lactobacillus in piglets in the GMF group (Fig. 1E).
  • Fig. 2 The fecal flora of piglets on the 21st day of birth is shown in Fig. 2, ⁇ -diversity, Fig. 2A and Fig. 2B show that the diversity (Sobs) index and Shannon index of the GMF group increased significantly; ⁇ -diversity, PCoA analysis showed that the CON group was significantly different from There were significant differences between the GMF groups (Fig. 2C); flora differences were shown at the genus level (Fig.
  • FIG. 3B On day 21, GMF intervention significantly enriched methane metabolism, arginine and proline metabolism, oxidative phosphorylation, phenylalanine, tyrosine and tryptophan biosynthesis, butyrate metabolism, lipid Biosynthetic proteins, propionate metabolism, valine, leucine and isoleucine degradation, beta-alanine metabolism, phenylalanine metabolism, tryptophan metabolism, RNA polymerase, limonene and pinene degradation , but decreased in genes linked to other ion-coupled transporters and other transporters.
  • the piglet model experiments showed that oral administration of GMF (galacto-oligosaccharide, ⁇ -lactalbumin powder, MFGM protein whey powder and polyfructose) in piglets could significantly improve growth performance and reduce plasma IgG levels.
  • GMF galacto-oligosaccharide, ⁇ -lactalbumin powder, MFGM protein whey powder and polyfructose
  • Produced probiotic colonization (Lactobacillus, Enterococcus and Robusia)
  • Our findings suggest that galactooligosaccharides, alpha-lactalbumin powder, milk fat globule membrane protein and polyfructose play very
  • the infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides of the present application is made of raw cow milk, supplemented with MFGM-rich whey protein powder, ⁇ -lactalbumin powder, galactooligosaccharide and It is prepared from polyfructose, and the content of biologically active substances with special functional ingredients such as MFGM-protein, lactoferrin (LF), ⁇ -lactalbumin ( ⁇ -La), etc. is increased through formula adjustment, so as to promote the intestinal bacteria of infants.
  • the colonization of probiotics in the colony significantly enriches the lactic acid bacteria in the intestinal tract, while reducing the unclassified bacteria and other miscellaneous bacteria, increasing the content of immune factors in the intestinal tract and reducing the incidence of intestinal diseases.
  • This formula is suitable for infants and older infants. Development of formula milk powder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法，以生牛乳作为原料乳，净乳后进行预杀菌，向预杀菌的生牛乳中添加MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料，预杀菌，均质，杀菌，浓缩，喷雾干燥制得婴幼儿配方奶粉；该婴幼儿配方奶粉通过配方调整提升具有特殊功能成分的生物活性物质MFGM-蛋白，乳铁蛋白、α-乳白蛋白、总低聚半乳糖、总多聚果糖、唾液酸、总磷脂、鞘磷脂、卵磷脂、磷脂酰丝氨酸、磷脂酰乙醇胺和磷脂酰肌醇、神经节苷脂、甘油三脂、甘油二脂的含量，达到促进婴儿肠道菌群中益生菌的定植尤其显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌，提高肠道中免疫因子的含量和降低肠道疾病发生率的目的，该配方适用于婴儿和较大婴儿配方乳粉的开发。

Description

一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法
交叉引用
本申请要求于2020年9月9日提交的、申请号为202010940024.0、发明名称为“一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法”的发明专利申请的优先权益，其全部内容通过引用并入本文。
技术领域
本申请涉及食品工程领域，尤其涉及一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法。
背景技术
分娩后婴儿的胃肠道结构和功能迅速适应从肠外营养(胎盘)向肠内营养(初乳/奶粉)的转变，在这个过程中并伴随着动态微生物定植。婴儿时期肠道微生物群的初步建立，参与肠道发育、代谢稳态和免疫防御多重相互作用，为以后长期健康奠定了关键基础。因此，新生儿肠道发育和微生物定植成为终生健康的窗口机会。由于出生后肠道微生态具有高度可塑性，在婴儿期易受营养摄入和周围环境的影响，宿主的健康生长需要优越的完整性和功能性肠道。此外，定植微生物群参与营养代谢，其代谢产物也有助于肠道屏障的完整性。因此，早期细菌最优定植影响了屏障功能，对肠道发育和新生儿生长起着至关重要的作用。
人乳是婴儿最理想的天然食物，已知人乳中有2000多种成分。人乳蛋白质也可以分为黏蛋白(mucins)、酪蛋白(casein)和乳清蛋白(whey)三组。黏蛋白也被称为乳脂肪球膜蛋白(milkfatglobulemembrane，MFGM)，MFGM是一种包裹乳脂球的脂质-蛋白质复合物，对肠道消化、生理和调节微生物种群产生有利影响，有相关报道称其能加速婴幼儿和仔猪的生长发育。乳脂肪球膜的脂质主要由中性脂和极性脂，以及少量的糖脂构成。磷脂是一种极性脂，是脂质的主要组成部分，可以促进脂肪消化产物在消化道的吸收和转运，同时磷脂还参与机体免疫调节和神经信号转导等功能。人乳脂肪球中主要存在的磷脂包括鞘磷脂(SM)、卵磷脂(PC)、磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)和磷脂酰肌醇(PI)。乳脂肪球膜的中性脂如甘油三职(TAG)、甘油二脂(DAG)、胆固醇及其脂类。
低聚半乳糖(GOS)和多聚果糖(FOS)是宿主微生物选择性利用的益生元，赋予益生元 在健康方面的作用。GOS和FOS的研究显示出对有益菌定殖的偏好，如乳酸菌，它对微生物菌群的代谢活性产生了与母乳低聚糖类似的影响。GOS和FOS在肠道发育和免疫应答方面也有很好的应用，GOS和FOS是肠道菌群发酵产生短链脂肪酸(short chain fatty acids,SCFAs)的益生元，对肠道的发育和生长具有有利作用。此外，源自牛奶的乳脂球膜(MFGM)在代谢调节和肠道稳态方面表现出营养生物活性。MFGM还能改变肠道菌群组成，增强肠道屏障功能。但婴儿期肠道发育和微生物定植是生长期的关键步骤，前人研究中关于MFGM研究和应用大多集中在组分分离、鉴定及通过代谢组学对其功能性质验证方面，但对婴儿肠道菌群定植、肠道微生态系统发育和屏障完整性的影响尚不清楚；GOS和MFGM干预的混合干预被报道可以改善仔猪的神经发育。但GOS、MFGM、FOS三者联合作用对肠道微生物组成和肠道发育的影响尚不明确。
发明内容
为解决现有技术问题，本申请的目的在于提供一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉。该奶粉以生牛乳为原料、填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成，通过配方调整提升具有特殊功能成分的生物活性物质MFGM-蛋白，乳铁蛋白(LF)、α-乳白蛋白(α-La)、总低聚半乳糖(GOS)、总多聚果糖(FOS)、唾液酸、总磷脂、鞘磷脂(SM)、卵磷脂(PC)、磷脂酰丝氨酸(PS)、磷脂酰乙醇胺(PE)和磷脂酰肌醇(PI)、神经节苷脂(Gang)、甘油三职(TAG)、甘油二脂(DAG))的含量，达到促进婴儿肠道菌群中益生菌的定植尤其显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌，提高肠道中免疫因子的含量和降低肠道疾病发生率的目的，该配方适用于婴儿和较大婴儿配方乳粉的开发。
本申请是通过下述技术方案实现的：
本申请提供一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉，以生牛乳为原料，填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成；其中每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.146-0.438g、总α-乳白蛋白0.22-0.35g、总乳铁蛋白0.2-0.6g、免疫球蛋白IgG0.1-0.3g、乳凝集素0.025-0.075g、MUC1/Mucin1 0.035-0.105g、总低聚半乳糖0.015-0.4g、总多聚果糖0.001-0.003g、唾液酸0.05-0.15g、总磷脂0.175-0.525g、神经鞘磷脂0.04-0.12g、神经节苷脂0.005-0.015g、卵磷脂0.06-0.19g、磷脂酰乙醇胺0.04-0.14g、磷脂酰肌醇0.02-0.06g、磷脂酰丝氨酸0.007-0.021g、甘油二脂0.0174-0.0371g、甘油三脂0.0311-0.0598g。见表1。
表1具有促进肠道健康的婴儿配方奶粉中功能活性成分的含量
Figure PCTCN2021113937-appb-000001
上述婴幼儿配方奶粉，其中按照1吨婴幼儿配方奶粉计，富含MFGM的乳清蛋白粉的添加量25kg-75kg，α-乳白蛋白粉添加量8kg-75kg，低聚半乳糖添加量44kg-133kg和多聚果糖添加量1.8kg-5.5kg；牛初乳按照100L鲜奶制成15-16公斤牛初乳粉填加。按照上述比例填加调配出的婴幼儿配方奶粉具有较高的总α-乳白蛋白活性成分。
进一步优选，按照1吨婴幼儿配方奶粉计，富含MFGM的乳清蛋白粉的添加量55kg-65kg，α-乳白蛋白粉添加量8kg-15kg，低聚半乳糖添加量97kg-115kg和多聚果糖添加量4kg-5kg。
牛乳α-乳白蛋白与人乳的α-乳白蛋白只有76％的氨基酸序列一致，α-乳白蛋白对婴儿具有非常高的营养价值，其氨基酸组成非常类似于婴儿氨基酸需要量及氨基酸模式。已证明α-乳白蛋白是乳糖合成酶的一部分，在乳腺参与乳糖的合成。乳糖合成酶由两种蛋白质组成，即α-乳白蛋白和半乳糖基转移酶，它们共同催化葡萄糖与UDP-半乳糖的结合。α-乳白蛋白在婴儿肠道中被消化时，产生的多肽具有抗菌、增强婴儿免疫力的作用；最近发现的α-乳白蛋白多聚体也具有抗感染、促进细胞凋亡的作用，这些功能对保护婴儿肠道健康具有重要意义。本申请的配方中特别填加了α-乳白蛋白协同提 高婴儿肠道健康的作用。
本申请上述婴幼儿配方奶粉中还可以添加其它配料如脂肪类、乳糖、矿物质、维生素及一些可选营养成分(胆碱、肌醇、牛磺酸、肉碱等)进行配料标准化后，调制出的婴儿配方乳粉具有促进婴儿肠道健康的作用。
本申请一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉的制备方法，包括如下步骤：以生牛乳作为原料乳，净乳后进行预杀菌(85℃-88℃，30s)，向预杀菌的生牛乳中添加MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料，预杀菌(85℃-88℃，30s)，均质15mPa，杀菌(93℃-95℃，15s)，浓缩，喷雾干燥(进风温度150℃-160℃，出风温度85℃-90℃)即可。
本申请所述的产品营养指标、理化指标、微生物指标及感官指标的检测严格按照食品安全国家标准婴儿配方食品(GB-10765-2010)指定的检测项目及检验方法进行。
本申请另一个具体实施例是涉及一种利用高通量测序技术对仔猪粪便中16S rDNA基因进行测序分析，考察了本申请的配方奶粉对生长发育与肠道菌群构成的影响。
有益效果
本申请开发的具有促进婴儿肠道健康的配方乳粉，通过添加富含MFGM的乳清蛋白粉、α发乳白蛋白粉、低聚半乳糖和多聚果糖，提高配方中具有特殊功能作用的总MFGM-蛋白、低聚半乳糖、多聚果糖、乳铁蛋白、α-乳白蛋白、IgG、乳凝集素、MUC1/Mucin1、磷脂、神经节苷脂、神经鞘磷脂和唾液酸多种功能活性成分的含量，使其尽量接近于母乳。新生儿出生后，哺乳动物的肠道形态和功能必须适应从无菌子宫到细菌丰富的环境的转变，因此，新生儿期是微生物定植的关键窗口。通过仔猪模型实验，口服本申请配方能够改善仔猪生长性能和降低血浆IgG水平，激活仔猪肠道内益生菌定植，显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌。增强肠道屏障功能通过提高基因的表达紧密连接(Occludin和ZO-1)，黏蛋白(Mucin-2和Mucin 4)和细胞因子(IL-1β和IL-22)，增强肠道屏障功能，提高新生仔猪的生长性能。我们的研究结果将为GOS、MFGM和FOS在调节婴儿早期肠道微生态中起着非常重要的作用,该产品适用于婴儿及较大婴儿配方乳粉的开发。
附图说明
图1是本申请实施例1的新生仔猪第八天粪便菌群组成：
其中图A是多样性(Sobs指数)；图B是香农指数(Shannon指数)；图C是基于未加权Unifrac距离的PCoA的β多样性；图D是基于Wilconxon秩和检验的差异微生物组成；图E是属水平的线性别分析效应大小(LefSe)分析，线性判别分析(LDA)评分>4；*P<0.05；**P<0.01。
图2是本申请实施例1的新生仔猪第21天粪便菌群组成：
其中图A是多样性(Sobs指数)；图B是香农指数(Shannon指数)；图C是基于未加权Unifrac距离的PCoA的β多样性；图D是基于Wilconxon秩和检验的差异微生物组成；图E是属水平的线性别分析效应大小(LefSe)分析，线性判别分析(LDA)评分>4；*P<0.05；**P<0.01。
图3是本申请实施例1的新生仔猪肠道菌群功能状况：
其中图A为第八天京都基因和基因组百科全书(KEGG)的差异丰度；图B为第二十一天京都基因和基因组百科全书(KEGG)的差异丰度。
图4是本申请实施例1 21天新生仔猪肠道屏障相关基因表达和肠道通透性的影响：
肠屏障相关基因在回肠粘膜(A-C)和结肠粘膜(D-F)中的表达；血浆DAO水平表达(G)。
图5是本申请实施例1的仔猪粪便SCFAs浓度及肠道GPRs基因的影响：
其中图A显示了仔猪粪便短链脂肪酸浓度差异，图B显示了受体基因表达情况。
图6是本申请实施例1的本申请的生产流程图。
具体实施方式
为使本申请的目的、技术方案和优点更加清楚，下面将结合本申请中的附图，对本申请实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例是本申请一部分实施例，而不是全部的实施例。基于本申请中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本申请保护的范围。除非另有其它明确表示，否则在整个说明书和权利要求书中，术语“包括”或其变换如“包含”或“包括有”等等将被理解为包括所陈述的元件或组成部分，而并未排除其它元件或其它组成部分。
实施例1婴儿配方奶粉中活性成分与母乳及对比例的比较，见表2
对比例：CN106359604A
表2
Figure PCTCN2021113937-appb-000002
Figure PCTCN2021113937-appb-000003
从上述比较可见，本申请的配方奶粉，活性成分更加全面接近母乳，尤其总α-乳白蛋白、卵磷脂、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰丝氨酸、甘油二脂、甘油三脂都是CN106359604A中不存在的成分。总乳铁蛋白要比对比例中高近10倍的量，与母乳减少差距。
表2中活性成分的按照下述方法调制而成，采用湿法加工工艺，图6所示。以生牛乳为原料乳，净乳后进行预杀菌，向预杀菌的生牛乳2000L中添加MFGM的乳清蛋白粉60kg、α-乳白蛋白粉10kg、低聚半乳糖106kg、多聚果糖4.33kg，均质，杀菌，浓缩，干燥即可。
上述方法中主要工艺参数为：所述预杀菌(85℃-88℃，30s)；均质15mPa；杀菌(93℃-95℃，15s)；喷雾干燥(进风温度150℃-160℃，出风温度85℃-90℃)。
本申请所述的产品营养指标、理化指标、微生物指标及感官指标的检测严格按照食品安全国家标准婴儿配方食品(GB-10765-2010)指定的检测项目及检验方法进行。
实施例2基于仔猪模型对产品影响肠道微生态评价
1.试验方法
1.1基仔猪模型建立和样本采集
选择16只仔猪(1.53±0.04公斤)从不同的窝(每窝一个仔猪)被随机分配到对照组喂食生理盐水(简称CON组)和实验组喂食低聚半乳糖、MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖(简称GMF组本申请实施例1)。新出生第1天至第7天，GMF组的仔猪每天使用5mLGMF溶液(1g/kg体重)，CON组仔猪饲喂等量生理盐水。在整个哺乳期，仔猪正常摄取母猪奶和水。商业饲料从产后第8天开始添加。每日 监测健康状况，记录第21天的体重；第21天，选择5只仔猪(约为每组平均体重)，并从颈静脉取样仔猪血样。在3000g下，在4℃下离心10分钟后，收集血浆。然后，收集粪便，并在液氮中快速冷冻，进行微生物组成分析。对仔猪安乐死后，将十二指肠、空肠和回肠标本固定在10％磷酸盐缓冲福尔马林中进行形态学评价。快速获得中柱和中柱的粘膜，并将其冷冻在液氮中进行基因表达鉴定。所有样品保存在-80℃，直到进一步分析。
1.2基于仔猪模型建立样本检测方法
1.2.1仔猪血浆样本检测
用ELISA方法测定仔猪血浆中二胺氧化酶(DAO)和免疫球蛋白(包括IgA、IgG和IgM)的含量。
1.2.2仔猪肠道微生态检测
从10％磷酸盐缓冲福尔马林液中取出肠道样品，通过分级乙醇系列(70％～100％)脱水，然后用二甲苯清除，并嵌入石蜡。连续切片(5μm厚)，利用成像显微镜，测量了至少15个完整和定向良好的绒毛及其每个片段的相关隐窝放大率。从绒毛尖端到绒毛隐窝交界处测量绒毛高度，并将隐窝深度定义为相邻绒毛之间的内陷深度。
1.2.3仔猪粪便高通量16S rRNA测序
用引物扩增16SrRNA基因的V3-V4区域，并用Axy PrepDNA凝胶提取试剂盒纯化。然后，将纯化的PCR产物汇集成等摩尔量，在平台上测序。
1.2.4仔猪粪便短链脂肪酸的测定
用离子色谱仪对仔猪粪便样本中短链脂肪酸包括乙酸、丙酸和丁酸在内进行定量分析。
2.结果
2.1 GMF对仔猪生长发育影响
2.1.1 GMF对仔猪体重影响
如表3所示，与CON组仔猪重要相比，GMF组显著增加了第8天和第14天仔猪的体重(P<0.05)。此外，GMF组1-8、1-21日平均日增重和全周期(1-21日)均有显著升高(P<0.05)。
表3 MFGM和LF对于仔猪体重影响
Figure PCTCN2021113937-appb-000004
Figure PCTCN2021113937-appb-000005
2.1.2 GMF对仔猪血浆中IgG浓度影响
如表4可知，第21天仔猪血浆中IgG浓度在GMF喂养后显著升高(p<0.05)，而Glu、IgA、IGM、TG、HDL-c和LDL-c等其他参数无差异。嗜乳脂蛋白(BTN)、粘蛋白(MUC)、黄黄嘌呤氧化还原酶(XOR)、乳黏素(MFG-E8)和脂肪酸结合蛋白(FABP)具有不同的生化特性。先前的研究表明，配方中的GMF补充剂对婴儿和动物的新生儿健康和肠道成熟具有促进生长的作用，本研究中血浆IgG水平的升高表明。
表4.MFGM和LF对于仔猪第21天的血浆影响
Figure PCTCN2021113937-appb-000006
2.1.3 GMF对仔猪肠形态道发育影响
为了确定仔猪的肠道形态发育，测定了仔猪的绒毛高度和隐窝深度(表5)。结果表明，GMF组可明显提高十二指肠和回肠的绒毛高度，而降低十二指肠隐窝深度(p<0.05)。
表5.MFGM对于仔猪第21天的肠道微生态影响
Figure PCTCN2021113937-appb-000007
Figure PCTCN2021113937-appb-000008
2.2 GMF对于仔猪肠道菌群影响
为了研究CON和GMF两组仔猪早期菌群的差异，采用16S rRNA高通量测序技术对其微生物多样性、组成及差异进行了评价。
2.2.1仔猪菌群构成
仔猪出生第8天粪便菌群如图1所示，α-多样性指数分析显示GMF组多样性(Sobs)指数明显下降(P<0.05)(图1A)，而香农指数不改变(图1B)；β-多样性，PCoA分析显示CON组和GMF组之间差异显著(图1C)；从菌群构成的角度，仔猪的差异菌群表明，GMF可以显著富集乳酸菌，减少未分类菌科(P<0.05)(图1D)。线性判别分析效应量(LEfSe)分析也证实GMF组仔猪乳酸菌显著升高(图1E)。
仔猪出生第21天粪便菌群如图2所示，α-多样性，图2A和图2B显示GMF组多样性(Sobs)指数和香农指数显著增加；β-多样性，PCoA分析显示CON组与GMF组之间存在显著差异(图2C)；在菌属水平上菌群差异显示(图2D拟杆菌、肠球菌、克里斯滕森菌和罗布西亚菌呈现增加趋势，而真杆菌属成员呈现下降趋势；线性判别分析效应量(LEfSe)分析显示(图2E)GMF组的拟杆菌、肠球菌、罗布西亚菌、g_反刍动物科_UCG-002、g_克里斯滕森_R-7_group、g_马文步里安提亚科、g_CHKCI001和未分类菌属在GMF组呈现显著上升趋势。
2.2.2仔猪菌群功能
为了进一步探索细菌群落的功能概况，我们利用KEGG数据库，通过PICRUSt，对群落进行系统发育研究。如图3A所示，第8天，GMF增加了糖酵解/糖异生作用、甘油脂代谢、MAPK信号通路、内噬作用、类黄酮生物合成、咖啡因代谢显著升高，而与卟啉和叶绿素代谢、氮代谢相关的基因降低。图3B第21天，GMF干预显著富集了甲烷代谢、精氨酸和脯氨酸代谢、氧化磷酸化、苯丙氨酸、酪氨酸和色氨酸生物合成、丁酸盐代谢、脂质生物合成蛋白、丙酸盐代谢、缬氨酸、亮氨酸和异亮氨酸降解、β-丙氨酸代谢、苯丙氨酸代谢、色氨酸代谢、RNA聚合酶、柠檬烯和蒎烯降解，但与其他离子偶联转运体和其他转运体连接的基因下降。
2.3GMF对仔猪肠道功能影响
2.3.1仔猪肠道屏障功能
为明确肠屏障功能和肠通透性，检测肠屏障相关基因在黏膜(回肠和结肠)和血浆DAO水平的表达。仔猪回肠紧密连接蛋白(E-钙黏着蛋白、ZO-1)(图4A)、粘蛋白(黏蛋白-1、黏蛋白-2、黏蛋白-4)(图4B)、IL-22(图4C)基因表达在GMF组中显著升高(P<0.05)。 同样，仔猪结肠中紧密连接蛋白的基因表达(封堵器表达，连接蛋白-1和ZO-1)(图4D)，黏蛋白-20(图4E)和细胞因子(TNF-α和IL-1β)(图4F)在GMF组中显著升高(P<0.05)。GMF组血浆DAO水平显著降低(P<0.05)(图4G)。
2.3.2仔猪粪便SCFAs浓度以及受体基因表达
仔猪粪便中SCFAs的浓度及其在肠道中的受体基因表达。结果表明，GMF组乙酸、丙酸和丁酸的浓度均显著高于CON组(p<0.05)(图5A)此外，GMF组增加了GPR41在结肠粘膜中的基因表达(图5B)。GMF组短链脂肪酸浓度及其受体(GPR41)升高促进了丙酸代谢，调节益生菌定植和短链脂肪酸代谢，最终激活了肠细胞，增强了肠道屏障功能。
综上所述，通过仔猪模型实验可知，口服GMF(低聚半乳糖、α-乳白蛋白粉、MFGM蛋白乳清粉和多聚果糖)仔猪可以显著提高生长性能和降低血浆IgG水平，出生后一周产生了益生菌定植(乳酸菌、肠球菌和罗布西亚菌)，促进了短链脂肪酸的产生，增强肠道屏障功能通过提高基因的表达紧密连接(封堵器蛋白和ZO-1)，黏蛋白(黏蛋白-2和黏蛋白-4)和细胞因子(IL-1β和IL-22)，因此提高仔猪的生长性能在整个新生儿期。我们的研究结果将为低聚半乳糖、α-乳白蛋白粉、乳脂肪球膜蛋白和多聚果糖在调节婴儿早期肠道微生态中起着非常重要的作用。
最后应说明的是：以上实施例仅用以说明本申请的技术方案，而非对其限制；尽管参照前述实施例对本申请进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本申请各实施例技术方案的精神和范围。
工业实用性
本申请的富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉是以生牛乳为原料、填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成，通过配方调整提升具有特殊功能成分的生物活性物质如MFGM-蛋白，乳铁蛋白(LF)、α-乳白蛋白(α-La)等的含量，达到促进婴儿肠道菌群中益生菌的定植尤其显著富集肠道内的乳酸菌同时减少未分类菌科等杂菌，提高肠道中免疫因子的含量和降低肠道疾病发生率的目的，该配方适用于婴儿和较大婴儿配方乳粉的开发。

Claims (10)

  1. 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉，其特征在于，所述婴幼儿配方奶粉以生牛乳为原料、填加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖和多聚果糖调制而成，其中每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.146-0.438g、总α-乳白蛋白0.22-0.35g、总乳铁蛋白0.2-0.6g、免疫球蛋白IgG0.1-0.3g、乳凝集素0.025-0.075g、MUC1/Mucin1 0.035-0.105g、总低聚半乳糖0.015-0.4g、总多聚果糖0.001-0.003g、唾液酸0.05-0.15g、总磷脂0.175-0.525g、神经鞘磷脂0.04-0.12g、神经节苷脂0.005-0.015g、卵磷脂0.06-0.19g、磷脂酰乙醇胺0.04-0.14g、磷脂酰肌醇0.02-0.06g、磷脂酰丝氨酸0.007-0.021g、甘油二脂0.0174-0.0371g、甘油三脂0.0311-0.0598g。
  2. 如权利要求1所述的婴幼儿配方奶粉，其特征在于，所述的每100克所述婴幼儿配方奶粉中功能活性成分的含量为总MFGM-蛋白0.438g、总α-乳白蛋白0.35g、总乳铁蛋白0.35g、免疫球蛋白IgG0.172g、乳凝集素0.075g、MUC1/Mucin1 0.105g、总低聚半乳糖0.4g、总多聚果糖0.003g、唾液酸0.15g、总磷脂0.525g、神经鞘磷脂0.12g、神经节苷脂0.015g、卵磷脂0.19g、磷脂酰乙醇胺0.14g、磷脂酰肌醇0.06g、磷脂酰丝氨酸0.021g、甘油二脂0.0371g、甘油三脂0.0598g。
  3. 如权利要求1所述的婴幼儿配方奶粉，其特征在于，按照1吨婴幼儿配方奶粉计，富含MFGM的乳清蛋白粉的添加量25kg-75kg，α-乳白蛋白粉添加量8kg-20kg，低聚半乳糖添加量44kg-133kg和多聚果糖添加量1.8kg-5.5kg；优选，按照1吨婴幼儿配方奶粉计富含MFGM的乳清蛋白粉的添加量55kg-65kg，α-乳白蛋白粉添加量7kg-15kg，低聚半乳糖添加量97kg-115kg和多聚果糖添加量4kg-5kg。
  4. 如权利要求1所述的婴幼儿配方奶粉，其特征在于，牛初乳按照100L鲜奶制成15-16公斤牛初乳粉填加。
  5. 如权利要求1-4任意一项所述的婴幼儿配方奶粉，其特征在于，按照生牛乳每2000L中添加MFGM的乳清蛋白粉60kg、α-乳白蛋白粉10kg、低聚半乳糖106kg、多聚果糖4.33kg。
  6. 如权利要求1所述的婴幼儿配方奶粉，其特征在于，所述的婴幼儿配方奶粉是通过下述方法调制而成的：以生牛乳作为原料乳，净乳后进行预杀菌85℃-88℃，30s，向预杀菌的生牛乳中添加富含MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料，预杀菌85℃-88℃，30s，均质15mPa，杀菌93℃-95℃，15s，浓缩，喷 雾干燥进风温度150℃-160℃，出风温度85℃-90℃即可。
  7. 如权利要求1所述的婴幼儿配方奶粉的制备方法，其特征在于，包括如下步骤：以生牛乳作为原料乳，净乳后进行预杀菌，向预杀菌的生牛乳中添加MFGM的乳清蛋白粉、α-乳白蛋白粉、低聚半乳糖、多聚果糖及其它配料，预杀菌，均质，杀菌，浓缩，喷雾干燥即可。
  8. 如权利要求7所述的婴幼儿配方奶粉的制备方法，其特征在于，所述预杀菌85℃-88℃，30s，均质条件15mPa，杀菌93℃-95℃，15s，喷雾干燥：进风温度150℃-160℃，出风温度85℃-90℃。
  9. 如权利要求1所述的婴幼儿配方奶粉在制备促进婴幼儿肠道益生菌富集的食品中的应用。
  10. 如权利要求1所述的婴幼儿配方奶粉在制备提高婴幼儿免疫力食品中的应用。
PCT/CN2021/113937 2020-09-09 2021-08-23 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法 WO2022052794A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021340764A AU2021340764B2 (en) 2020-09-09 2021-08-23 Infant formula milk powder rich in milk fat globule membrane protein, phospholipid and oligosaccharide, and preparation method therefor
US18/172,992 US20230263179A1 (en) 2020-09-09 2023-02-22 Infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010940024.0A CN112042750B (zh) 2020-09-09 2020-09-09 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法
CN202010940024.0 2020-09-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/172,992 Continuation US20230263179A1 (en) 2020-09-09 2023-02-22 Infant formula milk powder rich in milk fat globule membrane protein, phospholipids and oligosaccharides and preparation method therefor

Publications (1)

Publication Number Publication Date
WO2022052794A1 true WO2022052794A1 (zh) 2022-03-17

Family

ID=73609864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/113937 WO2022052794A1 (zh) 2020-09-09 2021-08-23 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法

Country Status (4)

Country Link
US (1) US20230263179A1 (zh)
CN (1) CN112042750B (zh)
AU (1) AU2021340764B2 (zh)
WO (1) WO2022052794A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115191509A (zh) * 2022-07-04 2022-10-18 江南大学 一种具有润肠通便功能的中老年雪糕
CN116616348A (zh) * 2023-07-21 2023-08-22 美赞臣婴幼儿营养品技术(广州)有限公司 含唾液酸的组合物及其在益生菌增殖和调节免疫中的应用
CN117652567A (zh) * 2024-02-02 2024-03-08 内蒙古蒙牛乳业（集团）股份有限公司 一种儿童配方牛奶及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112042750B (zh) * 2020-09-09 2022-04-05 北京三元食品股份有限公司 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法
CN116649420B (zh) * 2023-06-05 2024-05-24 高培（广州）乳业有限公司 一种营养益智、易消化吸收的营养奶粉及其制备方法
CN117378763B (zh) * 2023-12-12 2024-03-26 内蒙古伊利实业集团股份有限公司 具有免疫调节功能活性的营养组合物及其应用
CN117378762A (zh) * 2023-12-12 2024-01-12 内蒙古伊利实业集团股份有限公司 一种影响海马体中纤维束丰富程度的营养组合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106359604A (zh) * 2016-08-24 2017-02-01 北京三元食品股份有限公司 一种促进肠道健康的婴儿配方乳粉及其制备方法
CN106857855A (zh) * 2016-12-19 2017-06-20 北京三元食品股份有限公司 一种富含乳脂肪球膜和结构脂opo的婴儿配方乳粉及其制备方法
CN106912614A (zh) * 2017-03-10 2017-07-04 海普诺凯营养品有限公司 一种母乳化配方奶粉及其制作方法
CN108294112A (zh) * 2018-01-12 2018-07-20 雅士利国际婴幼儿营养品有限公司 优化蛋白质和氨基酸模式的婴儿配方奶粉及其制备方法
CN110477129A (zh) * 2019-09-14 2019-11-22 李钟� 一种富含乳脂球膜蛋白及磷脂的婴儿配方乳粉
CN112042750A (zh) * 2020-09-09 2020-12-08 北京三元食品股份有限公司 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
JP5959137B2 (ja) * 2006-12-28 2016-08-02 株式会社明治 乳由来リン脂質を含有する乳幼児脳発達促進剤及びそれを含有する食品組成物
BR112012013766A2 (pt) * 2009-12-08 2015-09-15 Nestec Sa "fórmula infantil com probióticos e componentes de membrana do glóbulo de gordura do leite"
AU2011370626A1 (en) * 2011-06-08 2013-11-28 Nestec S.A. Nutritional compositions having exogenous milk fat globule membrane components
CN102524422B (zh) * 2012-02-22 2014-01-29 浙江康恩贝健康产品有限公司 含α-乳白蛋白和乳铁蛋白的婴幼儿配方奶粉及制备方法
MX2012010488A (es) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Formula infantil para el optimo crecimiento, proteccion gastrointestinal y proteccion inmunologica de infantes.
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
MX2016006576A (es) * 2013-11-29 2016-08-03 Nestec Sa Composiciones nutritivas con fosfolipidos.
US20180133287A1 (en) * 2016-11-14 2018-05-17 Mead Johnson Nutrition Company Nutritional compositions providing dietary management of colic
US20180160714A1 (en) * 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
CN109007037B (zh) * 2018-10-16 2022-02-18 北京斯利安药业有限公司 一种增强婴幼儿免疫力的组合物及其产品与应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106359604A (zh) * 2016-08-24 2017-02-01 北京三元食品股份有限公司 一种促进肠道健康的婴儿配方乳粉及其制备方法
CN106857855A (zh) * 2016-12-19 2017-06-20 北京三元食品股份有限公司 一种富含乳脂肪球膜和结构脂opo的婴儿配方乳粉及其制备方法
CN106912614A (zh) * 2017-03-10 2017-07-04 海普诺凯营养品有限公司 一种母乳化配方奶粉及其制作方法
CN108294112A (zh) * 2018-01-12 2018-07-20 雅士利国际婴幼儿营养品有限公司 优化蛋白质和氨基酸模式的婴儿配方奶粉及其制备方法
CN110477129A (zh) * 2019-09-14 2019-11-22 李钟� 一种富含乳脂球膜蛋白及磷脂的婴儿配方乳粉
CN112042750A (zh) * 2020-09-09 2020-12-08 北京三元食品股份有限公司 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115191509A (zh) * 2022-07-04 2022-10-18 江南大学 一种具有润肠通便功能的中老年雪糕
CN115191509B (zh) * 2022-07-04 2023-09-26 江南大学 一种具有润肠通便功能的中老年雪糕
CN116616348A (zh) * 2023-07-21 2023-08-22 美赞臣婴幼儿营养品技术(广州)有限公司 含唾液酸的组合物及其在益生菌增殖和调节免疫中的应用
CN116616348B (zh) * 2023-07-21 2023-11-14 美赞臣婴幼儿营养品技术(广州)有限公司 含唾液酸的组合物及其在益生菌增殖和调节免疫中的应用
CN117652567A (zh) * 2024-02-02 2024-03-08 内蒙古蒙牛乳业（集团）股份有限公司 一种儿童配方牛奶及其制备方法
CN117652567B (zh) * 2024-02-02 2024-04-12 内蒙古蒙牛乳业（集团）股份有限公司 一种儿童配方牛奶及其制备方法

Also Published As

Publication number Publication date
CN112042750B (zh) 2022-04-05
AU2021340764B2 (en) 2022-12-08
CN112042750A (zh) 2020-12-08
AU2021340764A1 (en) 2022-06-23
US20230263179A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
WO2022052794A1 (zh) 一种富含乳脂肪球膜蛋白、磷脂和低聚糖的婴幼儿配方奶粉及其制备方法
Brink et al. Milk fat globule membrane: the role of its various components in infant health and development
Almeida et al. Bioactive compounds in infant formula and their effects on infant nutrition and health: A systematic literature review
JP6158380B2 (ja) 小腸に良い栄養組成物
Pieszka et al. Is mare milk an appropriate food for people?–a review
Walzem et al. Whey components: millennia of evolution create functionalities for mammalian nutrition: what we know and what we may be overlooking
Lima et al. Nutritional and health profile of goat products: focus on health benefits of goat milk
Playne et al. Functional dairy foods and ingredients
JP6234227B2 (ja) 腸内菌叢改善用栄養組成物
MX2007012697A (es) Formula para infantes con probioticos.
SE1250357A1 (sv) Näringssammansättning med lågt kalori- och lågt proteininnehåll
TWI629994B (zh) 包括乳鐵蛋白之營養組成物於刺激免疫細胞上之用途
Fantuz et al. Macro-and micronutrients in non-cow milk and products and their impact on human health
Ames et al. Comparing early life nutritional sources and human milk feeding practices: personalized and dynamic nutrition supports infant gut microbiome development and immune system maturation
JP2008540689A (ja) 哺乳動物の初乳又は乳汁由来の乳清分離分画を含む成長促進用食品組成物
TW201729824A (zh) 用於促進腸道屏障功能並減緩內臟疼痛之營養組成物
RU2658979C2 (ru) Детские смеси, содержащие оптимизированные профили аминокислот
CN102458135A (zh) 引发饱食感的奶制品
CN103429092A (zh) 包含乳铁蛋白的营养组合物在支持抵抗疾病和状况中的用途
US20220248738A1 (en) NUTRITIVE COMPOSITIONS WITH SECRETED IgA, MILK FAT GLOBULE MEMBRANE COMPONENTS AND/OR BIFIDOBACTERIUM
TWI761487B (zh) 用於促進血中胺基酸濃度上升之發酵乳
WO2018034345A1 (ja) 抗がん剤に起因する末梢神経障害を改善するための組成物
Tiwari et al. Nutritional Values and Therapeutic Uses of Capra hircus Milk.
RU2682257C2 (ru) Лактоферрин, улучшение памяти и повышение скорости обучения у детей
Zeinali et al. Intestinal dysbiosis in the infant and the future of lacto-engineering to shape the developing intestinal microbiome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21865850

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021340764

Country of ref document: AU

Date of ref document: 20210823

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21865850

Country of ref document: EP

Kind code of ref document: A1